J&J’s Codman Neuro inks distro deal with InNeuroCo

Johnson & Johnson‘s (NYSE:JNJ) Codman Neuro said last week it inked an exclusive U.S. and European distribution deal with InNeuroCo for its intermediate catheters designed for the minimally invasive treatment of hemorrhagic stroke.

Codman Neuro made the announcement at the Society of NeuroInterventional Surgery’s 13th annual meeting, Codman Neuro said.

“Intermediate catheters are increasingly used by neurovascular specialists to facilitate the delivery of other devices, including stents and thrombectomy devices for the treatment of stroke. This agreement with InNeuroCo demonstrates our commitment to neurovascular care and will help us strengthen our access portfolio and our ability to provide a total solution in this fast growing market,” Codman Neuro worldwide prez P. Laxminarain said in a press release.

Florida-based InNueroCo develops and manufactures neurovascular products designed to treat hemorrhagic stroke. The distro deal includes InNeuroCo’s intermediate catheter and super distal access device. The intermediate catheter has FDA and CE Mark approval, Codman Neuro said, while the super distal access device is pending FDA 510(k) clearance.

Codman Neuro will offer the catheters alongside its own microcatheters and guiding catheters designed to support the company’s Codman Enterprise 2 vascular reconstruction device.

Last July, Codman Neuro said it launched a new platform of embolic coils for the treatment of brain aneurysms.

The new platform of coils come with enhanced detachment systems that Codman Neuro said improve microcatheter stability. The coil’s delivery wires are marked with tactile fluoro markers to increase visibility during procedures, the company said.